Disease Markers
Special Issue on Epigenetic Biomarkers in Cancer CALL FOR PAPERS ere has been an explosion of interest in the epigenetics of cancer in the past decade. Lead Guest Editor DNA methylation is one of the major epigenetic mechanisms and it is a genetic Yuen Y. Cheng, University of Sydney, feature better reecting disease development and, consequently, has the potential to Sydney, Australia become more conclusive biomarker for detection and diagnosis of dierent diseases. [email protected] e presence of small amounts of tumor DNA in cell free DNA (CFDNA) circulating in the plasma or serum of cancer patients was rst demonstrated çý years ago. Since Guest Editors then, overall plasma DNA concentration in cancer patients and genetic or epigenetic Hong C. Jin, Zhejiang University, alterations specic to tumor DNA have been investigated in patients diagnosed with Zhejiang, China dierent types of cancer. However, the use of methylated DNA biomarkers is still [email protected] not widely used in the clinic and further eorts to establish detection methods are required. Michael W. Y. Chan, National Chung Cheng University, Chia-Yi, Taiwan e ubiquity of DNA methylation changes has opened the way to a host of [email protected] innovative diagnostic and therapeutic strategies. e status of DNA methylation is very stable, even in the circulation. us it can be assessed to monitor tumor- Wai K. Chu, Chinese University of related processes. ere is promising potential of DNA methylation as a diagnostic Hong Kong, Sha Tin, Hong Kong and prognostic marker for cancer patients due to the stability of circulating [email protected] DNA. Development of noninvasive biomarker assays from patient samples would allow early diagnosis, prognosis prediction, and continuing assessment of disease Michael Grusch, Medical University of progression and responses to treatments. Vienna, Vienna, Austria [email protected] e present special issue aims to publish high-quality research articles as well as review contributions on a variety of topics related to epigenetic biomarkers detection Manuscript Due in noninvasive clinical samples. Friday, òç June òýÔÞ
Potential topics include but are not limited to the following: First Round of Reviews Friday, Ô September òýÔÞ Types of epigenetic biomarkers and their signicance DNA methylation, circulating or noncirculating Publication Date MicroRNA and other noncoding RNA Friday, Ôý November òýÔÞ Protein markers Development of dierent nucleic acid methods using noninvasive samples Blood serum or plasma Urine Stool Sputum DNA methylation detection in noninvasive samples Blood serum or plasma Urine Stool Sputum Other nucleic acid (RNA and noncoding RNA) detections in noninvasive samples Dierent disease methylation markers using noninvasive methods DNA methylation in exfoliated cell in urine samples for urothelial/prostate cancer
Authors can submit their manuscripts through the Manuscript Tracking System at http://mts.hindawi.com/submit/journals/dm/ebmc/.